Accelerate Pheno System

by Accelerate Diagnostics, Inc.  · Based in United States → — Fully automated antibiotic susceptibility results with MICs direct from positive blood cultures using the Accelerate Pheno™ System.
Critical Care Infectious Disease Laboratory Medicine

Variable
Regulatory Status Disclosed

Overview

The Accelerate Pheno System is a fully automated in vitro diagnostic platform designed for rapid identification (ID) and antimicrobial susceptibility testing (AST) directly from positive blood cultures. It is NOT an AI tool for a physician directory. This system significantly reduces the time required to identify pathogens and determine their susceptibility to various antibiotics, often providing results in hours compared to the days required by conventional methods. Utilizing technologies like fluorescence in situ hybridization (FISH) for identification and morphokinetic cellular analysis (MCA) for susceptibility testing, the Accelerate Pheno System helps clinicians make targeted, life-saving therapy decisions earlier for patients with bacteremia and sepsis. This leads to improved patient outcomes, reduced length of hospital stay, and supports antimicrobial stewardship efforts by enabling optimal antibiotic selection and de-escalation.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Rapid Pathogen Identification (ID) in ~90 minutes to 2 hours
  • Rapid Antimicrobial Susceptibility Testing (AST) in ~5 to 7 hours
  • Directly from positive blood cultures
  • Fully automated workflow with minimal hands-on time
  • Utilizes Fluorescence In Situ Hybridization (FISH) for ID
  • Employs Morphokinetic Cellular Analysis (MCA) for AST
  • Provides Minimum Inhibitory Concentration (MIC) results
  • Supports targeted antibiotic therapy and de-escalation
  • Reduces time to optimal therapy by up to 26.4 hours and length of stay by up to 2.2 days
  • Expert rule system for susceptibility interpretation based on FDA/CLSI/EUCAST breakpoints

Use Cases

  • Rapid diagnosis of bloodstream infections
  • Guiding antibiotic therapy for sepsis patients
  • Enhancing antimicrobial stewardship programs
  • Reducing hospital length of stay for patients with infections
  • Optimizing antibiotic selection and dosage
  • Detecting antibiotic resistance faster

What Physicians Need to Know

LIS/LIMS Integration
The Accelerate Pheno System has LIS connectivity for automated reporting of results. It can integrate with LIS for automated resulting, including the implementation of automated LIS alerts (via text paging or email) to deliver actionable results to stewardship teams or providers.
Supported Assay Types
The system performs both identification (ID) and antimicrobial susceptibility testing (AST) directly from positive blood cultures. It utilizes fluorescence in situ hybridization (FISH) for identification and morphokinetic cellular analysis for phenotypic AST, providing Minimum Inhibitory Concentration (MIC) values. It identifies 14 common bacterial pathogens and two Candida species. The Accelerate PhenoTest BC kit identifies specific Gram-positive and Gram-negative bacteria and yeasts, including Staphylococcus aureus, Enterococcus faecalis, Enterococcus faecium, Pseudomonas aeruginosa, Escherichia coli, and Candida albicans, among others. It also tests susceptibility to a panel of antimicrobial agents such as amikacin, ampicillin, cefepime, meropenem, and vancomycin.
QC/QA Features
The system includes an automated quality control method. Quality control results for MIC evaluation are interpreted based on current EUCAST or CLSI guidelines. For the identification assay, the Quality Control Report indicates an overall status of “passed” or “failed” and lists identification results and pass/fail status for each tested species. For the AST assay, the Quality Control report lists the QC range, MIC, and pass/fail status for each antimicrobial agent.
Result Interpretation AI
The system uses computer algorithms to compare growth patterns of pathogens to an archive of patterns, which is a novel approach in clinical diagnostics. It provides MICs and categorical interpretations (susceptible [S], intermediate [I], or resistant [R]) based on FDA and/or CLSI breakpoints.
Critical Value Alerts
Integration with LIS allows for automated alerts (text or email) to be sent to stewardship teams or providers, facilitating timely intervention.
Instrument Interfaces
The Accelerate Pheno System is a fully automated platform. It is designed to work with the Accelerate PhenoTest BC kit. The system includes the Accelerate Pheno instrument, software, host computer, and analysis computer.
Reference Range Intelligence
MIC evaluation results are interpreted based on the current version of European Committee on Antimicrobial Susceptibility Testing (EUCAST) or Clinical and Laboratory Standards Institute (CLSI) guidelines. The system provides MICs and categorical interpretations (susceptible [S], intermediate [I], or resistant [R]) based on FDA and/or CLSI breakpoints.
Turnaround Time Impact
The system provides pathogen identification in approximately 90 minutes and AST results in about 7 hours directly from positive blood cultures. This significantly reduces turnaround time compared to conventional methods, which can take days. Studies have shown reductions in time to identification by 23.47 to 27.49 hours and AST by 31.2 to 41.86 hours. This rapid turnaround time can lead to earlier optimization of antibiotic therapy and improved patient outcomes.
Microbiology ID Support
The system uses automated fluorescence in situ hybridization (FISH) technology for rapid species identification. It identifies 14 common bacterial pathogens and two Candida species. The system also provides a unique "monomicrobial call" to indicate if only one bacteria is present in the blood culture. The overall sensitivity and specificity for organism identification have been reported as high as 95.6% and 99.5%, respectively. It can identify 16 organisms, including 6 Gram-positive and 8 Gram-negative bacteria, as well as 2 Candida species.
Physician Tip

The Accelerate Pheno System provides rapid identification and antimicrobial susceptibility testing directly from positive blood cultures, significantly reducing the time to results compared to traditional methods. This allows for earlier optimization of antibiotic therapy, which is crucial for patients with serious infections like sepsis. The system delivers MIC values and categorical interpretations based on established guidelines (CLSI/EUCAST), enabling informed decisions on antibiotic selection, dosage, and de-escalation. While highly accurate for on-panel organisms, be aware that polymicrobial infections or pathogens not included in the panel may require complementary testing. The integration with LIS and automated alerts can further streamline communication and facilitate timely clinical interventions.

The Accelerate Pheno System offers LIS/LIMS integration for automated reporting and alerts, enhancing workflow efficiency and communication within the laboratory and with clinical teams. It is designed to be a fully automated platform, working in conjunction with its proprietary Accelerate PhenoTest BC kit.

Details

Category Lab & Diagnostics, Triage & ER/ICU AI
Pricing Variable
DeploymentOn-premise (hospital microbiology laboratories)
Compliance
BAA AvailableUnknown
HIPAA CompliantUnknown
FDA Status Yes AI-estimated
Integrations
EHR Not specified
Specialties Critical Care, Infectious Disease, Laboratory Medicine

FDA clearance history

This product’s FDA authorization. From FDA’s list of AI-enabled medical devices; each number links to FDA’s record.

Decision dateNumberName as listed by FDA
2020-09-15K192665 510(k)Accelerate Pheno System

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Accelerate Pheno System

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money
No press coverage or publications on file yet. Know of some? Suggest an edit →

Videos

Product demos, reviews, and walkthroughs for Accelerate Pheno System.

View all on YouTube

Frequently Asked Questions

The Accelerate Pheno System can identify pathogens within 90 minutes and provide antimicrobial susceptibility testing (AST) results in approximately 7 hours directly from a positive blood culture. This is significantly faster than conventional methods, which can take 2-3 days.
The system enables physicians to optimize antibiotic therapy much sooner, potentially leading to a reduction in broad-spectrum antibiotic use, decreased length of hospital stay, and a statistically significant reduction in 30-day mortality for patients on ineffective empirical treatment.
While highly effective for many common pathogens, the system has limitations such as processing only one sample at a time per module, requiring samples to be processed within 8 hours of growth detection, and not currently including identification and AST for Gram-positive rods or AST for yeast. Additionally, some studies have shown suboptimal performance for certain antimicrobial-organism combinations, such as ampicillin-sulbactam against Enterobacterales and several antipseudomonal β-lactams against Pseudomonas aeruginosa.
Unlike some molecular diagnostic tests that are 'add-on' tests and only provide limited susceptibility information or detect resistance genes, the Accelerate Pheno System combines identification and rapid phenotypic AST into one instrument, providing phenotypic MIC susceptibility data. It offers significantly faster results than traditional methods and even other rapid methods like direct MALDI-TOF MS and VITEK 2 for both identification and AST.
The rapid identification and AST results from the Accelerate Pheno System are crucial for antimicrobial stewardship, allowing for timely de-escalation or escalation of antibiotic therapy. This can lead to more targeted treatment, reduced exposure to broad-spectrum antibiotics, and improved patient outcomes. Effective implementation often involves close collaboration between microbiology laboratories and antimicrobial stewardship teams.

Related Tools

PathologyAILab
PathologyAILab
Lab & Diagnostics
PathologyAILab provides AI-enhanced digital pathology analysis and diagnostic insights for healthcare providers, utilizing a multi-agent AI system for faster, more accurate cytology results.
Kneevoice Cartilage Evaluation System (750-3600-001)
Kneevoice
Lab & Diagnostics
Kneevoice develops innovative, non-invasive diagnostic devices to assess knee cartilage health by capturing and analyzing sounds produced by the knee joint during movement.
myosmart.cuff (757M20-2)
Otto Bock Healthcare Products GmbH
Lab & Diagnostics
The myosmart.cuff is a medical device by Otto Bock Healthcare Products GmbH designed for objective measurement of muscle tone, primarily for use in neurological rehabilitation.
Seaman Pro/Seaman
Checkcells
Lab & Diagnostics
CheckCells' Seaman PRO™ is an AI-powered microscope for automated semen analysis, offering high accuracy and efficiency for fertility diagnostics in clinics and at-home testing.
LensHooke X1 Pro Semen Quality Analyzer, LensHooke X1 Semen Quality Analyzer
Bonraybio Co.
Lab & Diagnostics
The LensHooke X1 Pro Semen Quality Analyzer and LensHooke X1 Semen Quality Analyzer are automated, compact devices that use AI optical microscopy for rapid and reliable human semen analysis, providing objective results for various sperm parameters.
Vitestro
Vitestro
General Productivity (AI Assistants)
Aletta by Vitestro is the world's first Autonomous Robotic Phlebotomy Device (ARPD) that automates diagnostic blood collection to improve standardization and address staffing shortages.

See all Lab & Diagnostics tools →

Suggest an Edit → | Report an issue | Last Verified: 2026-11-04 | First Added: 2026-04-17
AI Tool Finder
AI-powered search. Results may not be comprehensive.